Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
IPO Year:
Exchange: NYSE
Website: bd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/25/2025 | $211.00 | Sector Perform | RBC Capital Mkts |
| 5/22/2025 | $185.00 | Buy → Neutral | Citigroup |
| 5/2/2025 | $185.00 | Overweight → Neutral | Piper Sandler |
| 5/2/2025 | $192.00 | Buy → Neutral | Goldman |
| 5/2/2025 | Outperform → Mkt Perform | Raymond James | |
| 5/1/2025 | Overweight → Equal Weight | Wells Fargo | |
| 5/1/2025 | $190.00 | Buy → Neutral | BofA Securities |
| 5/1/2025 | Outperform → Mkt Perform | William Blair | |
| 10/1/2024 | $255.00 → $275.00 | Neutral → Buy | Citigroup |
| 5/30/2024 | $274.00 | Buy | Goldman |
Fastest customizable press release news feed in the world
Q4 revenue of $5.9 billion increased 8.3% as reported, 7.0% FXN and 3.9% organicQ4 GAAP and adjusted diluted EPS grew to $1.72 and $3.96, respectivelyFY25 revenue of $21.8 billion increased 8.2% as reported, 7.7% adjusted FXN and 2.9% organicFY25 GAAP EPS of $5.82 decreased 0.7%; adjusted diluted EPS of $14.40 grew 9.6%FY25 GAAP and adjusted gross margin up 20 basis points and 140 basis points, respectively, driven by BD ExcellenceFY25 GAAP operating margin down 10 basis points to 11.8%; adjusted operating margin up 80 basis points to 25.0%Returned $2.2 billion to shareholders in FY25 through dividends and share repurchasesCompany issues FY26 guidanceFRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNew
FRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of $1.05 per common share, an increase of 1.0% from the previous quarter. The dividend will be payable on December 31, 2025 to holders of record on December 8, 2025. The indicated annual dividend rate for fiscal year 2026 is $4.20 per share. "This is the 54th consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This inc
FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective, multi-center study evaluating the Revello™ Vascular Covered Stent in patients with peripheral arterial disease (PAD). The announcement was made in conjunction with a late-breaking clinical trial presentation at the VIVA (Vascular InterVentional Advances) 2025 conference by Dr. Sean Lyden, chair
FRANKLIN LAKES, N.J., Nov. 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Conformité Européenne (CE) marking in the European Union for its Enteric Bacterial Panel* (EBP) and Enteric Bacterial Panel plus* (EBP plus) for the BD COR™ System. By leveraging advanced Polymerase Chain Reaction (PCR) technology with streamlined testing for a broad range of gastrointestinal (GI) bacterial pathogens from a single stool swab samp
FRANKLIN LAKES, N.J., Oct. 22, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced a new self-collection solution for HPV testing in markets outside the United States. This new innovation simplifies at-home sample collection for patients and further automates lab processing using high-tech robotics with the BD COR™ System. The new swab technology has been certified through the In Vitro Diagnostic Medical Device Regulation (IVDR) in Europe, which is also recognized by many other countries around the wo
FRANKLIN LAKES, N.J., Oct. 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a global leader in medical technology, introduces the BD Incada™ Connected Care Platform, a new scalable, AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem for the first time. The BD Incada™ Platform is available now with the launch of the next-generation BD Pyxis™ Pro Automated Medication Dispensing Solution, creating enterprise-wide visibility and connectivity that transforms data into actionable insight. "Our vision for the BD Incada
BROKEN BOW, Neb., Oct. 16, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, proudly commemorates 65 years of manufacturing excellence at its Broken Bow, Nebraska facility—a cornerstone of BD's extensive U.S. manufacturing network. Since opening its doors on Oct. 18, 1960, the Broken Bow site has grown from a 13,753-square-foot steel building with 20 associates to a 310,000-square-foot facility employing nearly 600 dedicated BD associates. Today, Broken Bow stands as the world's largest manufacturer of BD Vacutaine
Provides Preliminary Revenue for Fourth Quarter and Full Year Fiscal 2025 FRANKLIN LAKES, N.J., Oct. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today a transition plan under which Chris DelOrefice, executive vice president and chief financial officer (CFO), will depart the company effective Dec. 5, 2025, to pursue a new professional opportunity. The company is conducting a search to identify a permanent successor. Vitor Roque, senior vice president of finance, business units and corporate financial planning and analysis, has been named interim CFO and will assume the role effective upon DelOrefice's departur
FRANKLIN LAKES, N.J., Oct. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, November 6, 2025 to discuss the Company's financial results for its fourth quarter and full year of fiscal 2025, which ended on September 30, 2025, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation material
FRANKLIN LAKES, N.J., Oct. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the enrollment of the first patient in the XTRACT™ Registry, a prospective, multi-center, single-arm, post-market registry study designed to evaluate the real-world performance of the Rotarex™ Catheter System in the treatment of patients with peripheral artery disease (PAD) lesions. The XTRACT™ Registry is being led in partnership with Co-Principal Investigators, Dr. Prakash Krishnan, an interventional cardiologist, and
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
RBC Capital Mkts initiated coverage of Becton Dickinson with a rating of Sector Perform and set a new price target of $211.00
Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00
Piper Sandler downgraded Becton Dickinson from Overweight to Neutral and set a new price target of $185.00
Goldman downgraded Becton Dickinson from Buy to Neutral and set a new price target of $192.00
Raymond James downgraded Becton Dickinson from Outperform to Mkt Perform
Wells Fargo downgraded Becton Dickinson from Overweight to Equal Weight
BofA Securities downgraded Becton Dickinson from Buy to Neutral and set a new price target of $190.00
William Blair downgraded Becton Dickinson from Outperform to Mkt Perform
Citigroup upgraded Becton Dickinson from Neutral to Buy and set a new price target of $275.00 from $255.00 previously
Goldman initiated coverage of Becton Dickinson with a rating of Buy and set a new price target of $274.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa
For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
10-Q - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
425 - BECTON DICKINSON & CO (0000010795) (Subject)
425 - BECTON DICKINSON & CO (0000010795) (Subject)
425 - BECTON DICKINSON & CO (0000010795) (Subject)
425 - BECTON DICKINSON & CO (0000010795) (Subject)
425 - BECTON DICKINSON & CO (0000010795) (Subject)
Live finance-specific insights
Q4 revenue of $5.9 billion increased 8.3% as reported, 7.0% FXN and 3.9% organicQ4 GAAP and adjusted diluted EPS grew to $1.72 and $3.96, respectivelyFY25 revenue of $21.8 billion increased 8.2% as reported, 7.7% adjusted FXN and 2.9% organicFY25 GAAP EPS of $5.82 decreased 0.7%; adjusted diluted EPS of $14.40 grew 9.6%FY25 GAAP and adjusted gross margin up 20 basis points and 140 basis points, respectively, driven by BD ExcellenceFY25 GAAP operating margin down 10 basis points to 11.8%; adjusted operating margin up 80 basis points to 25.0%Returned $2.2 billion to shareholders in FY25 through dividends and share repurchasesCompany issues FY26 guidanceFRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNew
FRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of $1.05 per common share, an increase of 1.0% from the previous quarter. The dividend will be payable on December 31, 2025 to holders of record on December 8, 2025. The indicated annual dividend rate for fiscal year 2026 is $4.20 per share. "This is the 54th consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This inc
Provides Preliminary Revenue for Fourth Quarter and Full Year Fiscal 2025 FRANKLIN LAKES, N.J., Oct. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today a transition plan under which Chris DelOrefice, executive vice president and chief financial officer (CFO), will depart the company effective Dec. 5, 2025, to pursue a new professional opportunity. The company is conducting a search to identify a permanent successor. Vitor Roque, senior vice president of finance, business units and corporate financial planning and analysis, has been named interim CFO and will assume the role effective upon DelOrefice's departur
Revenue of $5.5 billion increased 10.4% as reported, 8.5% adjusted FXN and 3.0% organicGAAP and adjusted diluted EPS grew to $2.00 and $3.68, respectivelyGAAP and adjusted gross margin up 160 basis points and 50 basis points, respectively, driven by BD ExcellenceGAAP and adjusted operating income up 46.6% and 11.3%, respectivelyCompany raises full-year adjusted diluted EPS guidance to $14.30 to $14.45, reflecting an $0.18 increase to 9.4% growth at the midpoint, while reaffirming organic revenue growth guidance1Expects to complete remaining $250 million of $1 billion share buyback commitment by the end of fiscal 2025FRANKLIN LAKES, N.J., Aug. 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and
FRANKLIN LAKES, N.J., July 22, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on September 30, 2025 to holders of record on September 8, 2025. The indicated annual dividend rate is $4.16 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that he
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growthCreates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brandsAnticipate approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three, and $290 million of revenue synergies by year five Delivers a
Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organicGAAP and adjusted diluted EPS of $1.07 and $3.35, respectivelyCompany updates full-year fiscal 2025 guidance and provides estimated tariff impactFRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025. "Amid a difficult operating environment impacting near-term organic revenue growth, our Q2 results reflect the strength of our business model and ability to exceed our earnings expectations through quality gross margin improvement," s
FRANKLIN LAKES, N.J., April 29, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on June 30, 2025 to holders of record on June 9, 2025. The indicated annual dividend rate is $4.16 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advanc
Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organicGAAP and adjusted diluted EPS of $1.04 and $3.43 grew 8.3% and 28.0%, respectivelyBD completes $750 million share repurchase to date in FY25Company increases FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency1FRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 first quarter which ended December 31, 2024. "We delivered strong operational performance in Q1, with
Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation "New BD," built on momentum of BD 2025 strategy, will be well-positioned as a scaled, pure-play MedTech leader focused on attractive categories shaping the future of health careBiosciences and Diagnostic Solutions to realize its full market potential as differentiated leader in Life Sciences Tools and Diagnostics, with robust innovation pipeline and headroom for growth in key sectorsFRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announ
Live Leadership Updates
FRANKLIN LAKES, N.J., Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE:BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations. https://loveyourlimbs.com to learn more or get involved." alt="September is Peripheral Artery Disease Awareness Month. Visit https://loveyourlimbs.com to learn more or get involved."> PAD affects more than 21 million Americans1 and more than 200 milli
FRANKLIN LAKES, N.J., July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has been named executive vice president and will become the president of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances its New BD strategy. Mushin will serve as a member of the BD Executive Leadership Team reporting to Tom Polen, chairman, CEO and president of BD and will lead the strategy development to support an effective transition into this new structure over the next several months.
FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive experience, having held chief executive officer and senior leadership roles across finance, corporate strategy and business development f
SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have
Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply
Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /CNW/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /PRNewswire/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio
Industry Veteran Herman Cueto Named CFO Azenta CFO Lindon Robertson to Retire Company Reaffirms Guidance for Fourth Quarter Fiscal 2023 BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16. Mr. Cueto, who comes from BD ((Becton, Dickinson and Company, NYSE:BDX), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Steve Schwartz, Azenta President and Chief
FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors. Waldstreicher, 63, was most recently the chief medical officer for Johnson & Johnson (J&J), serving in this capacity from 2012 until her retirement in 2023. As chief medical officer, she provided visionary strategic and operational leadership at J&J, with global responsibility for safety, epidemiology, regulatory and clinical operations transformatio
This live feed shows all institutional transactions in real time.
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)